Category: 349-49-5

Electric Literature of 349-49-5, Children learn through play, and they learn more than adults might expect. Science experiments are a great way to spark their curiosity, get their minds active, and encourage them to do something that doesn’t involve a screen. 349-49-5, C4H3F3N2S. A document type is Patent, introducing its new discovery.

The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.

The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.

If you are hungry for even more, make sure to check my other article about 349-49-5. Electric Literature of 349-49-5

Reference£º
Thiazole | C3H4900NS – PubChem,
Thiazole | chemical compound | Britannica

Children learn through play, and they learn more than adults might expect. Science experiments are a great way to spark their curiosity, get their minds active, and encourage them to do something that doesn¡¯t involve a screen. 349-49-5, C4H3F3N2S. A document type is Patent, introducing its new discovery., Application In Synthesis of 4-(Trifluoromethyl)thiazol-2-amine

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1a, R2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1a, R2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Interested yet? Keep reading other articles of 349-49-5!, Application In Synthesis of 4-(Trifluoromethyl)thiazol-2-amine

Reference£º
Thiazole | C3H4901NS – PubChem,
Thiazole | chemical compound | Britannica

349-49-5, Name is 4-(Trifluoromethyl)thiazol-2-amine, molecular formula is C4H3F3N2S, belongs to thiazole compound, is a common compound. In a patnet, once mentioned the new application about 349-49-5, Application In Synthesis of 4-(Trifluoromethyl)thiazol-2-amine

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Application In Synthesis of 4-(Trifluoromethyl)thiazol-2-amine. In my other articles, you can also check out more blogs about 349-49-5

Reference£º
Thiazole | C3H4902NS – PubChem,
Thiazole | chemical compound | Britannica

A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 349-49-5, Name is 4-(Trifluoromethyl)thiazol-2-amine, molecular formula is C4H3F3N2S. In a Patent£¬once mentioned of 349-49-5, Application In Synthesis of 4-(Trifluoromethyl)thiazol-2-amine

The invention disclosed herein are embodiments of compounds capable of treating a viral infection. For example, the compounds are capable of inhibiting viral downmodulation of major histocompatibility complex I (MHC-I), such as by acting as immunomodulators of the immune system to treat, cure or eradicate a viral infection (e.g., HIV infection). More particularly, the present disclosure relates to the use of a heteroaryl compound or salts or analogs thereof, in the treatment of patients infected with a virus. The disclosed compounds may be used alone or in combination with other pharmacologically active agents to treat, cure or eradicate the virus, particularly in patients with persistent, latent viral infection. In some embodiments, the disclosed compounds can be used alone or in combination with other pharmacologically active agents to promote reactivation of viral production in latent cells and eradication of such cells.

The invention disclosed herein are embodiments of compounds capable of treating a viral infection. For example, the compounds are capable of inhibiting viral downmodulation of major histocompatibility complex I (MHC-I), such as by acting as immunomodulators of the immune system to treat, cure or eradicate a viral infection (e.g., HIV infection). More particularly, the present disclosure relates to the use of a heteroaryl compound or salts or analogs thereof, in the treatment of patients infected with a virus. The disclosed compounds may be used alone or in combination with other pharmacologically active agents to treat, cure or eradicate the virus, particularly in patients with persistent, latent viral infection. In some embodiments, the disclosed compounds can be used alone or in combination with other pharmacologically active agents to promote reactivation of viral production in latent cells and eradication of such cells.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Application In Synthesis of 4-(Trifluoromethyl)thiazol-2-amine. In my other articles, you can also check out more blogs about 349-49-5

Reference£º
Thiazole | C3H4910NS – PubChem,
Thiazole | chemical compound | Britannica

349-49-5, Name is 4-(Trifluoromethyl)thiazol-2-amine, molecular formula is C4H3F3N2S, belongs to thiazole compound, is a common compound. In a patnet, once mentioned the new application about 349-49-5, Recommanded Product: 349-49-5

Phenylethylthiazolylthiourea (PETT) derivatives have been identified as a new series of nonnucleoside inhibitors of HIV-1 RT. Structure-activity relationship studies of this class of compounds resulted in the identification of N-[2-(2-pyridyl)ethyl]-N’-[2-(5-bromopyridyl)]-thiourea hydrochloride (trovirdine; LY300046.HCl) as a highly potent anti-HIV-1 agent. Trovirdine is currently in phase one clinical trials for potential use in the treatment of AIDS. Extension of these structure-activity relationship studies to identify additional compounds in this series with improved properties is ongoing. A part of this work is described here. Replacement of the two aromatic moleties of the PETT compounds by various substituted or unsubstituted heteroaromatic rings was investigated. In addition, the effects of multiple substitution in the phenyl ring were also studied. The antiviral activities were determined on wild-type and constructed mutants of HIV-1 RT and on wild-type HIV-1 and mutant viruses derived thereof, Ile100 and Cys181, in cell culture assays. Some selected compounds were determined on double- mutant viruses, HIV-1 (Ile100/Asn103) and HIV-1 (Ile100/Cys181). A number of highly potent analogs were synthesized. These compounds displayed IC50’s against wild-type RT between 0.6 and 5 nM. In cell culture, these agents inhibited wild-type HIV-1 with ED50’s between I and 5 nM in MT-4 cells. In addition, these derivatives inhibited mutant HIV-1 RT (Ile 100) with IC50’s between 20 and 50 nM and mutant HIV-1 RT (Cys 181) with IC50’s between 4 and 10 nM, and in cell culture they inhibited mutant HIV-1 (Ile100) with ED50’s between 9 and 100 nM and mutant HIV-1 (Cys181) with ED50’s between 3 and 20 nM.

Phenylethylthiazolylthiourea (PETT) derivatives have been identified as a new series of nonnucleoside inhibitors of HIV-1 RT. Structure-activity relationship studies of this class of compounds resulted in the identification of N-[2-(2-pyridyl)ethyl]-N’-[2-(5-bromopyridyl)]-thiourea hydrochloride (trovirdine; LY300046.HCl) as a highly potent anti-HIV-1 agent. Trovirdine is currently in phase one clinical trials for potential use in the treatment of AIDS. Extension of these structure-activity relationship studies to identify additional compounds in this series with improved properties is ongoing. A part of this work is described here. Replacement of the two aromatic moleties of the PETT compounds by various substituted or unsubstituted heteroaromatic rings was investigated. In addition, the effects of multiple substitution in the phenyl ring were also studied. The antiviral activities were determined on wild-type and constructed mutants of HIV-1 RT and on wild-type HIV-1 and mutant viruses derived thereof, Ile100 and Cys181, in cell culture assays. Some selected compounds were determined on double- mutant viruses, HIV-1 (Ile100/Asn103) and HIV-1 (Ile100/Cys181). A number of highly potent analogs were synthesized. These compounds displayed IC50’s against wild-type RT between 0.6 and 5 nM. In cell culture, these agents inhibited wild-type HIV-1 with ED50’s between I and 5 nM in MT-4 cells. In addition, these derivatives inhibited mutant HIV-1 RT (Ile 100) with IC50’s between 20 and 50 nM and mutant HIV-1 RT (Cys 181) with IC50’s between 4 and 10 nM, and in cell culture they inhibited mutant HIV-1 (Ile100) with ED50’s between 9 and 100 nM and mutant HIV-1 (Cys181) with ED50’s between 3 and 20 nM.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Recommanded Product: 349-49-5. In my other articles, you can also check out more blogs about 349-49-5

Reference£º
Thiazole | C3H4916NS – PubChem,
Thiazole | chemical compound | Britannica

349-49-5. Chemistry is the experimental science by definition. We want to make observations to prove hypothesis. For this purpose, we perform experiments in the lab. 349-49-5, Name is 4-(Trifluoromethyl)thiazol-2-amine,introducing its new discovery.

The identification and structure-activity-relationships (SARs) of novel 2-amino benzamide glucokinase activators are described. Compounds in this series were developed to be potent GK activators, and their binding mode to the GK protein was determined by crystal structure analysis. In vivo pharmacokinetic and acute in vivo efficacy studies of compound 18 are also described.

The identification and structure-activity-relationships (SARs) of novel 2-amino benzamide glucokinase activators are described. Compounds in this series were developed to be potent GK activators, and their binding mode to the GK protein was determined by crystal structure analysis. In vivo pharmacokinetic and acute in vivo efficacy studies of compound 18 are also described.

349-49-5, If you are hungry for even more, make sure to check my other article about 349-49-5

Reference£º
Thiazole | C3H4911NS – PubChem,
Thiazole | chemical compound | Britannica

349-49-5, 4-(Trifluoromethyl)thiazol-2-amine is a thiazole compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

EXAMPLE 3 2-Imino-3-methyl-4-trifluoromethyl-4-thiazoline fluorosulfonate 336 mg. of 2-amino-4-trifluoromethylthiazole was dissolved in 15 mg. CH2 Cl2. The flask was placed in an ice bath and 240 mg. of CH3 SO3 F in 5 ml. CH2 Cl2 was added. The mixture was then placed in a refrigerator over the weekend. The colorless crystals were collected on a filter to give 450 mg. (80percent) of 2-imino-3-methyl-4-trifluoromethyl-4-thiazoline fluorosulfonate, m.p. 177¡ã-178¡ã C., 349-49-5

The synthetic route of 349-49-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Merck & Co., Inc.; US4029803; (1977); A;,
Thiazole | C3H3NS – PubChem
Thiazole | chemical compound | Britannica

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.349-49-5,4-(Trifluoromethyl)thiazol-2-amine,as a common compound, the synthetic route is as follows.

To a solution of 5-(1-methylsulfanyl-ethyl)2-trifluoromethylpyridine (0.5 g, 2.25 mmol) and 2-amino-4-trifluoromethyl thiazole (0.42 g, 2.48 mmol) in dichloromethane (8 ml) cooled to -25¡ã C. was slowly added N-chlorosuccinamide (0.33 g, 2.48 mmol) while maintaining the internal temperature of the reaction between -22¡ã C. and -28¡ã C. The reaction was slowly warmed to room temperature and stirred an additional hour. The reaction mixture was washed with water and the dichloromethane layer was dried (MgSO4), filtered and concentrated to dryness. The crude product was purified by chromatography on silica gel (eluent: 50percent EtOAc/hexanes, 100percent EtOAc) to give 3-[1-ethyl(N-(2-(4-trifluromethyl)thiazole)-sulfinyl)(methyl)]-6-trifluoromethylpyridine (G) as a yellow solid (0.81 g, 93percent ); M+H=288.1., 349-49-5

The synthetic route of 349-49-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Dow AgroSciences LLC; US2009/29863; (2009); A1;,
Thiazole | C3H3NS – PubChem
Thiazole | chemical compound | Britannica

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.349-49-5,4-(Trifluoromethyl)thiazol-2-amine,as a common compound, the synthetic route is as follows.

(Example 48) 4-Hydroxy-4-(trifluoromethyl)-3-{1-[4-(trifluoromethyl)1,3-thiazol-2-yl]piperidin-4-yl}-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-b]pyridin-6-one (hereinafter, referred to as compound 48-a)[0476] Copper(II) chloride (2.90 g, 21.57 mmol) was added to a solution of 2-amino-4-(trifluoromethyl)thiazole (3.05 g, 18.14 mmol) in acetonitrile (80 mL), then isoamyl nitrite (3.60 mL, 27.04 mmol) was added dropwise thereto at 0¡ãC, and the mixture was stirred at room temperature for 1 hour and at 50¡ãC for 2 hours. Then, the solvent in the reaction solution was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [elute: hexane/ethyl acetate = 100/0 – 70/30 (gradient)] to obtain an oil (1.12 g)._: [0478] 4-Hydroxy-3-(piperidin-4-yl)-4-(trifluoromethyl)-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-b]pyridin-6-one (62 mg, 0.18 mmol) produced in Reference Example 60 and N,N-diisopropylethylamine (40 muL, 0.24 mmol) were added to a solution of the obtained oil (55 mg) in dimethyl sulfoxide (2 mL), and the mixture was stirred at room temperature for 5 hours and further at 0¡ãC for 2 hours and 30 minutes. The reaction solution was diluted with ethyl acetate, washed with water and brine, and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography [elute: hexane/ethyl acetate = 70/30 – 10/90 (gradient)] to obtain the title compound 48-a (6 mg, yield: 6percent) and compound 48-b (18 mg, yield: 16percent). Compound 48-a 1H-NMR (400 MHz, DMSO-d6) delta: 12.29 (1H, s), 10.53 (1H, s), 7.54 (1H, s), 6.79 (1H, s), 4.05-3.96 (2H, m), 3.40-3.20 (1H, m), 3.14 (2H, t, J = 12 Hz), 2.90 (1H, d, J = 16 Hz), 2.73 (1H, d, J = 16 Hz), 1.94-1.74 (4H, m); MS (ESI) m/z: 456 (M+H)+.Compound 48-b 1H-NMR (400 MHz, DMSO-d6) delta: 12.27 (1H, s), 10.54 (1H, s), 8.61 (1H, s), 6.80 (9H, s), 4.10 (2H, d, J = 13 Hz), 3.33-3.18 (3H, m), 2.90 (1H, d, J = 16 Hz), 2.73 (1H, d, J = 16 Hz), 1.99-1.74 (4H, m); MS (ESI) m/z: 607 (M+H)+., 349-49-5

As the paragraph descriping shows that 349-49-5 is playing an increasingly important role.

Reference£º
Patent; Daiichi Sankyo Company, Limited; KOBAYASHI, Hideki; OHKAWA, Nobuyuki; TAKANO, Daisuke; KUBOTA, Hideki; ONODA, Toshio; KANEKO, Toshio; ARAI, Masami; TERASAKA, Naoki; EP2862861; (2015); A1;,
Thiazole | C3H3NS – PubChem
Thiazole | chemical compound | Britannica